

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

---

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 5, 2020**

---

**Insys Therapeutics, Inc.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35902**  
(Commission File Number)

**51-0327886**  
(IRS Employer  
Identification No.)

**3100 West Ray Road Ste. 201**  
**Chandler, Arizona**  
(Address of Principal Executive Offices)

**85226**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (480) 500-3127**

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.\*

<u>Title Of Each Class</u>	<u>Trading Symbol</u>	<u>Name Of Each Exchange On Which Registered</u>
<b>Common Stock, \$0.01 Par Value Per Share</b>	<b>INSYQ</b>	<b>N/A</b>

\* On June 24, 2019, a Form 25 relating to the delisting and deregistration under Section 12(b) of the Act of the registrant's common stock was filed by The Nasdaq Stock Market LLC. The registrant's common stock trades on the OTC Pink Sheets Market.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

## **Item 7.01 Regulation FD Disclosure.**

As previously disclosed, on June 10, 2019, Insys Therapeutics, Inc. (the “Company”) and its subsidiaries (collectively, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions,” and the cases commenced thereby, the “Chapter 11 Cases”) for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).

On February 5, 2020, the Company filed its monthly operating report for the period beginning November 1, 2019 and ending November 30, 2019 (the “Monthly Operating Report”) with the Bankruptcy Court. The Monthly Operating Report is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This Current Report on Form 8-K (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

In accordance with General Instruction B.2 of Form 8-K, the information being furnished under this Item 7.01 pursuant to this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

### *Cautionary Statements Regarding Trading in the Company’s Securities*

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Cases. As previously disclosed, on the effective date of the *Second Amended Joint Chapter 11 Plan of Liquidation of Insys Therapeutics, Inc. and Its Affiliated Debtors* that was confirmed by the Bankruptcy Court on January 16, 2020 (as further amended, supplemented or modified in accordance with its terms, the “Plan”), all existing shares of the Company’s common stock will be cancelled.

### **Cautionary Statements Regarding Forward-Looking Information**

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intend” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. All statements, other than statements of historical facts, included in this filing that address activities, events or developments that the Company expects, believes, targets or anticipates will or may occur in the future are forward-looking statements. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of certain risks and other factors, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the terms of and potential transactions contemplated by the Plan and the related disclosure statement, the Company’s ability to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents, Bankruptcy Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general, risks associated with third-party motions in the Chapter 11 Cases, the potential adverse effects of the Chapter 11 Cases on the Company’s liquidity or results of operations and increased legal and other professional costs necessary to execute the Company’s reorganization; uncertainty associated with the Company’s ability to complete the sale of its remaining assets as contemplated by the Bankruptcy Petitions; trading price and volatility of the Company’s common stock as well as other risk factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC in addition to those factors, risks and uncertainties described in more detail in the Company’s risk factors set forth in Exhibit 99.1 to the Current Report on Form 8-K filed by the Company with the SEC on August 8, 2019. The Company therefore cautions readers against relying on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on the Company’s behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and, except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Additional Information Regarding the Chapter 11 Cases**

Bankruptcy Court filings and other information related to the Chapter 11 Cases are or will be available at a website administered by the Company’s noticing and claims agent, Epiq Corporate Restructuring, LLC, at <https://dm.epiq11.com/Insys>. Information contained on, or that can be accessed through, such website or the Bankruptcy Court’s website is not part of this Current Report.

---

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Monthly Operating Report, for the period covering November 1, 2019 through November 30, 2019, filed with the United States Bankruptcy Court for the District of Delaware</a>

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 10, 2020

Insys Therapeutics, Inc.

By: /s/ Andrece Housley  
Name: Andrece Housley  
Title: Chief Financial Officer

**UNITED STATES BANKRUPTCY COURT  
DISTRICT OF DELAWARE**

**In re:**  
**Insys Therapeutics, Inc.; et al.**  
**Debtors**

**Case No. 19-11292 (KG)**  
**Reporting Period: November 1 – November 30, 2019**

**MONTHLY OPERATING REPORT**  
Reporting Period: November 1, 2019 – November 30, 2019

<b>REQUIRED DOCUMENTS</b>	<b>Form No.</b>	<b>Document Attached</b>	<b>Explanation Attached</b>	<b>Affidavit/ Supplement Attached</b>
Schedule of Cash Receipts and Disbursements	MOR-1	X		
Bank Account Balances, Debtor Statement with Respect to Bank Account Reconciliations	MOR-1a	X		See Attestation
Schedule of Professional Fees and Expenses Paid	MOR-1b	X		
Copies of bank statements				See Attestation
Cash disbursements journals				See Attestation
Statement of Operations by Legal Entity	MOR-2	X		
Balance Sheet by Legal Entity	MOR-3	X		
Status of Postpetition Taxes				See Attestation
Summary of Unpaid Postpetition Debts	MOR-4	X		
Accounts Receivable Reconciliation and Aging	MOR-5	X		
Debtor Questionnaire	MOR-6	X		

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

/s/ Andrece Housley

Signature of Debtor

Andrece Housley

Chief Financial Officer of Insys Therapeutics, Inc.; et al.

2/5/2020

Date

**Notes to the Monthly Operating Report**  
Reporting Period: November 1, 2019 – November 30, 2019

**General:**

The report includes activity from the following Debtors and related Case Numbers:

Case Number	Debtor Name
19-11292	Insys Therapeutics, Inc.
19-11293	IC Operations, LLC
19-11294	Insys Development Company, Inc.
19-11295	Insys Manufacturing, LLC
19-11296	Insys Pharma, Inc.
19-11297	IPSC, LLC
19-11298	IPT 355, LLC

This Monthly Operating Report is unaudited and has been prepared solely for the purpose of complying with the Debtors' obligations to provide monthly operating reports currently during these Chapter 11 Cases. This MOR is not prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and does not include all the information and footnotes required by U.S. GAAP. The Debtors have prepared this Monthly Operating Report using the best information presently available to them, which has been collected, maintained, and prepared in accordance with their historical accounting practices. This Monthly Operating Report is, thus, true and accurate to the best of the Debtors' knowledge, information and belief based on current available data.

**General Methodology:** The Debtors prepared this Monthly Operating Report relying primarily upon the information set forth in their books and records. Consequently, certain transactions that are not identified in the normal course of business in the Debtors' books and records may not be included in this Monthly Operating Report. Additionally, the information furnished in this report includes primarily normal recurring adjustments, but does not include all the adjustments that would typically be made for the quarterly and annual consolidated financial statements to be in accordance with U.S. GAAP. Furthermore, the monthly financial information contained herein has not been subjected to the same level of accounting review and testing that the Debtors apply in the preparation of their quarterly and annual consolidated financial information in accordance with U.S. GAAP. Accordingly, upon the application of such procedures, the Debtors believe that the financial information may be subject to change, and these changes could be material. Nevertheless, in preparing this Monthly Operating Report, the Debtors made best efforts to supplement the information set forth in their books and records with additional information concerning transactions that may not have been identified therein.

**Liabilities Subject to Compromise:** The payment of prepetition indebtedness is subject to compromise or other treatment under a chapter 11 plan of reorganization. The determination of the amount of such liabilities and how the liabilities will be settled and treated cannot be made until a Chapter 11 Plan of Reorganization is approved by the Bankruptcy Court. Liabilities subject to compromise have been reported at the amounts recorded on the Debtor's books and records. The amounts classified as liabilities subject to compromise in the financial statements and supplemental schedules included herein are preliminary and may be subject to future adjustments depending on claims filed on and before the bar date, Bankruptcy Court actions, developments with respect to disputed claims, rejection of executory contracts, reconciliation of claims, and other events.

**Reservation of Rights:** Given the complexity of the Debtors' business, inadvertent errors, omissions or over inclusion of contracts may have occurred. Accordingly, the Debtors hereby reserve all of their rights to dispute the validity, status, enforceability, or executory nature of any claim amount, representation or other statement in this Monthly Operating Report and reserve the right to amend or supplement this Monthly Operating Report, if necessary.

**General Notes**

On June 10, 2019 (the "Petition Date"), Insys Therapeutics, Inc. ("Insys Therapeutics") and its affiliated debtors each commenced a voluntary case under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). The Debtors are authorized to operate their business and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The Debtors' chapter 11 cases are being jointly administered for procedural purposes only under case number 19-11292 (KG) pursuant to Rule 1015(b) of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules").

Additional information about the Chapter 11 Cases, court filings and claims information is available on the internet at <https://dm.epiq11.com/case/Insys/dockets>

**MOR-1**  
**Consolidated Schedule of Cash Receipts and Disbursements**

Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#		For the Period Ended November 30, 2019	Cumulative 6/10/19 - 11/30/19
1	<b><u>Operating Receipts</u></b>		
2	Sales Receipts (after GTN settled by credit)	\$ 2,880,407	\$ 17,844,700
3	Sales Deductions	-	-
4	Other Receipts	839,010	1,476,705
5	<b>Total Operating Receipts</b>	<b>3,719,417</b>	<b>19,321,405</b>
6	<b><u>Operating Disbursements</u></b>		
7	Employee Related	(863,398)	(8,548,232)
8	Rent (Equipment & Buildings) & Utilities	(30,593)	(1,146,048)
9	Manufacturing Costs	-	(59,642)
10	Gross-to-Nets (Direct Pay)	(750,038)	(1,988,192)
11	Consulting / Prof. Fees	(63,549)	(472,706)
12	Legal	(1,256,182)	(2,152,955)
13	Research and Development / Regulatory	(116,145)	(2,927,169)
14	Sales & Marketing	-	(152,036)
15	General and Administrative	(70,161)	(1,001,575)
16	Insurance	(72,712)	(242,017)
17	Board of Directors Fees	(88,500)	(748,308)
18	Advancements to BTcP	(2,908,645)	(5,818,467)
19	<b>Total Operating Disbursements</b>	<b>(6,219,922)</b>	<b>(25,257,347)</b>
20	<b>Operating Cash Flow</b>	<b>(2,500,505)</b>	<b>(5,935,942)</b>
21	<b><u>Bankruptcy Related Disbursements</u></b>		
22	Professional Fees	(9,164,570)	(14,984,889)
23	Vendor Deposits & Critical Vendors	-	(127,247)
24	<b>Total Bankruptcy Related Disbursements</b>	<b>(9,164,570)</b>	<b>(15,112,135)</b>
25	<b>Net Cash Flow</b>	<b>(11,665,075)</b>	<b>(21,048,078)</b>
26	<b><u>Cash Balance<sup>(1)</sup></u></b>		
27	Beginning Cash Balance	59,038,793	38,019,624
28	Net Cash Flow	(11,665,075)	(21,048,078)
29	363 Sale Proceeds	-	30,402,171
30	<b>Ending Cash Balance</b>	<b>\$ 47,373,718</b>	<b>\$ 47,373,718</b>

**Footnotes:**

(1) Cash balance represents book balance, which is net of outstanding checks and may differ from Bank Balance due to items in-transit and other timing items.

**MOR-1 (Continued)**  
**Consolidated Schedule of Cash Receipts and Disbursements**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

November Distribution by Debtor								
	INSYS THERAPEUTICS, INC.	INSYS PHARMA, INC.	INSYS DEVELOPMENT COMPANY, INC.	IPSC, LLC	INSYS MANUFACTURING, LLC	IC OPERATIONS, LLC	IPT 355, LLC	TOTAL
Total Disbursements	\$ 13,960,274	\$ -	\$ 212,031	\$ 1,869	\$ 216,923	\$ 993,396	\$ -	\$ 15,384,493

**MOR-1a**  
**Bank Account Balances, Debtor Statement with Respect to Bank Account Reconciliations**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#	Case Number	Debtor Entity	Account Number	Bank	Account Type	For the Period Ended 11/30/2019(1)
1	19-11293	IC Operations, LLC	XXXXX5620	Western Alliance	Checking	582,041
2	19-11293	IC Operations, LLC	XXXXX9623	Western Alliance	Checking	-
3	19-11294	Insys Development Company, Inc.	XXXXX5187	Western Alliance	Checking	165,854
4	19-11294	Insys Development Company, Inc.	XXXXX3863	Western Alliance	Checking	-
5	19-11295	Insys Manufacturing, LLC	XXXXX7170	Western Alliance	Checking	167,777
6	19-11295	Insys Manufacturing, LLC	XXXXX1178	Western Alliance	Checking	-
7	19-11292	Insys Therapeutics, Inc.	XXXXX5031	JP Morgan	Checking/ CC Deposit	70,189
8	19-11292	Insys Therapeutics, Inc.	XXXXX7833	Western Alliance	Money Market	3,931,443
9	19-11292	Insys Therapeutics, Inc.	XXXXX7655	Western Alliance	Professional Fee Escrow	3,999,990
10	19-11292	Insys Therapeutics, Inc.	XXXXX3750	Western Alliance	Utilities Deposit	31,500
11	19-11292	Insys Therapeutics, Inc.	XXXXX9735	Wells Fargo	Cash	37,967,261
12	19-11292	Insys Therapeutics, Inc.	XXXXX7215	Western Alliance	Lease Agreement Account	267,000
13	19-11292	Insys Therapeutics, Inc.	XXXXX5149	Western Alliance	Checking	137,447
14	19-11292	Insys Therapeutics, Inc.	XXXXX9155	Western Alliance	Checking	-
15	19-11297	IPSC, LLC	XXXXX3630	Western Alliance	Checking	53,216
16	19-11297	IPSC, LLC	XXXXX7638	Western Alliance	Checking	-
<b>17</b>					<b>Total</b>	<b>\$ 47,373,718</b>

**Footnotes:**

(1) Cash balance represents book balance, which is net of outstanding checks and may differ from Bank Balance due to items in-transit and other timing items.



---

In re:  
Insys Therapeutics, Inc.; et al.  
Debtors

Case No. 19-11292 (KG)  
Reporting Period: November 1 – November 30, 2019

---

**MOR-1a**

**Debtor Attestation to with Respect to Bank Account Reconciliations, Bank Statements and Open/Closed Bank Accounts**

Reporting Period: November 1, 2019 – November 30, 2019

**Bank Account Reconciliations & Cash Disbursement Journal**

The Debtors affirm that bank account reconciliations are prepared for all open and active bank accounts on a monthly basis. The Debtors affirm that within their financial accounting systems, check registers and/or disbursement journals are maintained for each disbursement account.

**Bank Statement**

The Debtors affirm that bank statements for all open and active bank accounts are retained by the Debtors.

**Open/Closed Bank Accounts**

The Debtors did not open or close any bank accounts during November.

/s/ Andrece Housley \_\_\_\_\_  
Andrece Housley  
Chief Financial Officer of Insys Therapeutics, Inc.; et al.

2/5/2020  
\_\_\_\_\_  
Date

**MOR-1b**  
**Schedule of Professional Fees and Expenses Paid**  
 Reporting Period: November 1, 2019 – November 30, 2019  
 (\$'S IN USD)

#	Payee	Role	Period Covered		Payment Date	Amount Paid this Period		Amount Paid Case to Date	
			Beginning Date	End Date		Fees	Expenses	Fees	Expenses
1	Weil, Gotshal & Manges LLP	Debtor Counsel	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	\$ 2,893,570	\$ 200,044	\$ 5,145,628	\$ 214,320
2	Richards, Layton, & Finger, P.A.	Local Debtor Counsel	November 01, 2019	November 30, 2019	Week Ended 11/22	228,428	-	1,146,176	36,981
3	FTI Consulting, Inc.	Debtor Financial Advisor	November 01, 2019	November 30, 2019	N/A	-	-	-	-
4	Lazard Ltd.	Debtor Investment Banker	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	1,830,000	-	2,150,000	2,972
5	Epiq Global	Claims Agent	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	38,164	1,226,972	38,164	1,226,972
6	Akin Gump Strauss Hauer & Field LLP	UCC Counsel	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	1,520,371	15,918	3,705,346	41,576
7	Bayard, P.A.	UCC Local Counsel	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	249,837	1,970	489,933	7,599
8	Province, Inc.	UCC Financial Advisor	November 01, 2019	November 30, 2019	Week Ended 11/8 and 11/22	833,332	4,061	1,677,764	9,704
<b>9</b>	<b>Total</b>					<b>\$ 7,593,701</b>	<b>\$ 1,448,965</b>	<b>\$ 14,353,010</b>	<b>\$ 1,540,124</b>

**MOR-2**  
**Statement of Operations by Legal Entity**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#	Category	Insys Therapeutics, Inc.	IC Operations, LLC	Insys Development Company, Inc.	Insys Manufacturing, LLC	Insys Pharma, Inc.	IPSC, LLC	IPT 355, LLC	Eliminations	Consolidated
		Case No. 19-11292	Case No. 19-11293	Case No. 19-11294	Case No. 19-11295	Case No. 19-11296	Case No. 19-11297	Case No. 19-11298		11/1/19-11/30/19
1	Net Revenue	\$ -	\$ (12,718)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (12,718)
2	Cost of Revenue	-	-	-	(121,173)	-	-	-	-	(121,173)
<b>3</b>	<b>Total Gross Profit</b>	-	<b>(12,718)</b>	-	<b>121,173</b>	-	-	-	-	<b>108,456</b>
<b>4</b>	<b>Operating expenses</b>									
5	Selling	-	(47,709)	-	-	-	1,679	-	-	(46,029)
6	Marketing	-	7,063	-	-	-	-	-	-	7,063
7	Research and development	-	-	(102,485)	(2,473,252)	-	-	-	-	(2,575,621)
8	General and administrative	7,144,605	357,859	-	-	(234,137)	-	-	-	7,268,212
9	Restructuring Fees <sup>(1)</sup>	4,747,050	-	-	-	-	-	-	-	4,747,050
10	Intercompany fees	-	-	-	-	-	-	-	-	-
11	Charges related to litigation award	515,137	-	-	-	-	-	-	-	515,137
<b>12</b>	<b>Total Operating Expenses</b>	<b>12,406,792</b>	<b>317,213</b>	<b>(102,485)</b>	<b>(2,473,137)</b>	<b>(234,252)</b>	<b>1,679</b>	-	-	<b>9,915,811</b>
<b>13</b>	<b>Income (loss) from operations</b>	<b>(12,406,792)</b>	<b>(329,931)</b>	<b>102,485</b>	<b>2,594,310</b>	<b>234,252</b>	<b>(1,679)</b>	-	-	<b>(9,807,356)</b>
<b>14</b>	<b>Other income (expense), net:</b>									
15	Interest income (expense)	58,318	-	-	-	-	-	-	-	58,318
16	Other income (expense), net	98,405	-	-	-	-	-	-	-	98,405
17	Total other income (expense), net	156,723	-	-	-	-	-	-	-	156,723
18	Income (loss) before income taxes:	(12,250,070)	(329,931)	102,485	2,594,310	234,252	(1,679)	-	-	(9,650,633)
19	Income tax expense (benefit)	-	-	-	-	-	-	-	-	-
<b>20</b>	<b>Net income (loss)</b>	<b>\$ (12,250,070)</b>	<b>\$ (329,931)</b>	<b>\$ 102,485</b>	<b>\$ 2,594,310</b>	<b>\$ 234,252</b>	<b>\$ (1,679)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ (9,650,633)</b>

**Footnotes:**

(1) Restructuring Fees for all entities are shown at Insys Therapeutics and include accrued fees for restructuring professionals.

**MOR-3**  
**Balance Sheet by Legal Entity**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#	Category	Insys Therapeutics, Inc.	IC Operations, LLC	Insys Development Company, Inc.	Insys Manufacturing, LLC	Insys Pharma, Inc.	IPSC, LLC	IPT 335, LLC	Eliminations	Consolidated
		Case No. 19-11292	Case No. 19-11293	Case No. 19-11294	Case No. 19-11295	Case No. 19-11296	Case No. 19-11297	Case No. 19-11298		11/30/19
1	<b>Assets</b>									
2	<b>Current Assets</b>									
3	Cash and cash equivalents	\$ 46,373,330	\$ 613,541	\$ 165,854	\$ 167,777	\$ -	\$ 53,216	\$ -	\$ -	47,373,718
4	Short-term investments	(0)	-	-	-	-	-	-	-	(0)
5	Intercompany	327,924,399	(12,319,393)	(8,499,913)	(351,136,435)	84,113,960	2,347,066	-	(42,429,683)	-
6	Trade accounts receivable, net	6,447,265	3,591,352	20	-	(2,672,932)	-	-	-	7,365,705
7	Intercompany accounts receivable	-	-	-	300,969,097	-	-	-	(300,969,097)	-
8	Inventory, net	-	1,833,694	-	(102,323)	-	-	-	(1,968,453)	(237,082)
9	Prepaid expenses and other assets	6,106,248	27,216	97,456	28,544	22,732	44,787	-	(108,000)	6,218,982
10	Deferred tax asset, current	-	-	-	-	-	-	-	-	-
11	<b>Total Current Assets</b>	386,851,241	(6,253,590)	(8,236,853)	(50,073,340)	81,463,760	2,445,068	-	(345,475,233)	60,721,323
12	Fixed assets, net	6,640	(1,360)	470,080	1,684,141	-	0	-	-	2,159,501
13	Operating lease right-of-use assets	-	-	454,804	(0)	-	-	-	-	454,804
14	Long-term investments	518,219	-	-	-	-	-	-	-	518,219
15	Intangible asset	-	-	-	-	-	-	-	-	-
16	Goodwill	-	-	-	-	-	-	-	-	-
17	Investment in subsidiary	27,693,643	-	-	-	-	-	-	(27,693,643)	-
18	Deferred tax asset, non-current	-	-	-	-	1	-	-	-	1
19	Other assets	3,265,052	317,648	42,000	380,000	148,000	-	-	-	4,152,700
20	<b>Total Assets</b>	\$ 418,334,795	\$ (5,937,301)	\$ (7,269,699)	\$ (48,009,199)	\$ 81,611,760	\$ 2,445,068	\$ -	\$ (373,168,876)	\$ 68,006,548
21	<b>Liabilities And Stockholders' Equity (Deficit)</b>									
22	<b>Current Liabilities</b>									
23	Accounts payable and accrued expenses	\$ 34,225,724	\$ 5,429,953	\$ 3,672,725	\$ 1,357,413	\$ 51,708,267	\$ 7,723	\$ -	\$ -	\$ 96,401,805
24	Intercompany accounts payable	-	5,685,434	-	-	295,283,663	-	-	(300,969,097)	-
25	Accrued compensation	702,068	329,207	707,319	468,232	94,867	2,966	-	-	2,304,659
26	Accrued sales allowances	-	2,911,515	-	-	1,121,465	10,913	-	-	4,043,892
27	Current portion of operating lease liabilities	-	-	327,287	143	-	-	-	-	327,430
28	Accrued litigation awards and settlements	76,753,021	-	-	-	62,635,173	-	-	-	139,388,194
29	Deferred revenue	-	-	-	-	-	-	-	-	-
30	Bank line of credit	-	-	-	-	-	-	-	-	-
31	Notes payable to related party, including interest	-	-	-	-	-	-	-	-	-
32	<b>Total Current Liabilities</b>	111,680,814	14,356,109	4,707,331	1,825,787	410,843,434	21,602	-	(300,969,097)	242,465,979
33	Contingent payment obligation	177,653,955	-	-	-	-	-	-	-	177,653,955
34	Operating lease liability	-	-	210,756	-	-	-	-	-	210,756
35	Uncertain income tax position	3,861,119	-	-	-	-	-	-	-	3,861,119
36	Other non-current liabilities	-	-	-	94,319	-	-	-	-	94,319
37	Notes payable to related party, including interest, long term	-	-	-	-	-	-	-	-	-
38	<b>Total Liabilities</b>	293,195,888	14,356,109	4,918,087	1,920,106	410,843,434	21,602	-	(300,969,097)	424,286,129
39	Commitments and contingencies	-	-	-	-	-	-	-	-	-
40	<b>Stockholders' Equity (Deficit)</b>									
41	Convertible preferred stock	-	-	-	-	-	-	-	-	-
42	Common stock	746,389	-	-	-	145,989	-	-	(145,677)	746,702
43	Additional paid in capital	575,021,594	-	-	-	59,117,800	-	-	(335,217,966)	298,921,428
44	Unrealized gain/loss on investments	(76,998)	-	-	-	-	-	-	-	(76,998)
45	Unrealized gain/loss on foreign exchange	-	-	-	-	-	-	-	-	-
46	Notes receivable from stockholders	-	-	-	-	-	-	-	-	-
47	Retained earnings	(302,745,683)	-	35,795,428	(2,408,524)	(298,163,466)	2,549,010	-	228,890,242	(336,082,993)
48	Current period retained earnings (accumulated deficit)	(147,806,397)	(20,293,410)	(47,983,215)	(47,520,780)	(90,331,996)	(125,543)	-	34,273,622	(319,787,719)
49	<b>Total Stockholders' Equity (Deficit)</b>	125,138,906	(20,293,410)	(12,187,787)	(49,929,305)	(329,231,674)	2,423,467	-	(72,199,779)	(356,279,581)
50	<b>Total Liabilities And Stockholders' Equity (Deficit)</b>	\$ 418,334,795	\$ (5,937,301)	\$ (7,269,699)	\$ (48,009,199)	\$ 81,611,760	\$ 2,445,068	\$ -	\$ (373,168,876)	\$ 68,006,548

**Debtor Attestation with Respect to Postpetition Taxes**

Reporting Period: November 1, 2019 – November 30, 2019

Andrece Housley hereby declares under penalty of perjury:

I am Chief Financial Officer of Insys Therapeutics, Inc., et al., the above captioned debtors and debtors in possession (collectively the "Debtors"). I am familiar with the Debtors day-to-day operations, business affairs and books and records. I am authorized to submit this statement on behalf of the Debtors.

All statements in this statement are based on my personal knowledge, my review of the relevant documents, my discussions with other employees of the Debtors, or my opinion based upon my experience and knowledge of the Debtors' operations and financial condition. If I were called upon to testify, I could and would testify to each of the facts set forth herein based on such personal knowledge, review of documents, discussions with other employees of the Debtors or opinion.

To the best of my knowledge, information and belief, and except as otherwise set forth in the MOR, all of the Debtors have filed all the necessary federal, state and local tax returns, or extensions related there to, and have timely made (or are in the process of remediating any immaterial late filings or prepayments) all related required postpetition tax payments, which are not subject to dispute or reconciliation, and are current.

/s/ Andrece Housley  
Andrece Housley  
Chief Financial Officer of Insys Therapeutics, Inc.; et al.

2/5/2020  
Date

**MOR-4**  
**Summary of Unpaid Postpetition Debts**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#	Accounts Payable	Current	Days Past Due				Total
			0 - 30 Days	31 - 60 Days	61 - 90 Days	> 91 Days	
1	Combined Debtors(1)(2)	\$ 14,879	\$ 1,329,392	\$ 1,063,788	\$ 633,105	\$ 2,865,430	\$ 5,906,593

**Footnotes:**

- (1) The postpetition accounts payable represents open and outstanding trade vendor invoices that have been entered into the Debtors' accounts payable system and do not include accruals. This summary does not include intracompany and intercompany payables.
- (2) Trade Payables per balance sheet include accruals and non-cash entries not due and payable per accounts payable aging.

**MOR-5**  
**Accounts Receivable Reconciliation and Aging**  
Reporting Period: November 1, 2019 – November 30, 2019  
(\$'s in USD)

#	Accounts Receivable Reconciliation	Beginning Accounts Receivable	Change in Accounts Receivable	Ending Accounts Receivable
1	IC Operations, LLC <sup>(1)</sup>	\$ 6,989,639	\$ (3,067,935)	\$ 3,921,704
2	Insys Therapeutics, Inc. <sup>(1)</sup>	3,532,121	2,908,645	6,440,766
3	Total Accounts Receivable	\$ 10,521,760	\$ (159,290)	\$ 10,362,470

#	Accounts Receivable Aging	Current	Days Past Due				Total
			0 - 30 Days	31 - 60 Days	61 - 90 Days	> 91 Days	
1	IC Operations, LLC <sup>(2)</sup>	\$ 827,731	\$ 506,987	\$ 639,101	\$ 397,743	\$ 1,550,142	\$ 3,921,704
2	Insys Therapeutics, Inc. <sup>(2)</sup>	5,818,467	622,299	-	-	-	6,440,766
3	Total Accounts Receivable	\$ 6,646,198	\$ 1,129,287	\$ 639,101	\$ 397,743	\$ 1,550,142	\$ 10,362,470

**Footnotes:**

- (1) Amounts are shown on a gross basis before any adjustment for estimated bad debts and other uncollectable amounts. This summary does not include any accrued fees, discounts or intracompany and intercompany receivables.
- (2) Amounts are aged from the due date and are included on a gross basis before any adjustment for estimated bad debts and other uncollectable amounts. This summary does not include any accrued fees, discounts or intracompany and intercompany receivables.

**MOR-6**  
**DEBTOR QUESTIONNAIRE**

Reporting Period: November 1, 2019 – November 30, 2019

<b>Must be completed each month</b>	<b>Yes</b>	<b>No</b>
1. Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X
2. Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		X
3. Have all postpetition tax returns been timely filed? If no, provide an explanation below.	X	
4. Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	X	
5. Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.		X